A phase 2 trial of PDS0101B in patients with HPV-related head and neck cancer
Latest Information Update: 11 Feb 2016
Price :
$35 *
At a glance
- Drugs PDS 0101 (Primary)
- Indications Head and neck cancer; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors PDS Biotechnology Corporation
- 11 Feb 2016 New trial record
- 09 Feb 2016 According to PDS Biotechnology media release, this trial is expected to initiate in 2016 and 2017.